SCHEMBL1623326

SCHEMBL1623326

CCOC(=O)c1ccn[nH]c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
MAPT P10636 2/20 0.51
KDM4E B2RXH2 2/20 0.51
TSHR P16473 1/20 0.50
JMJD6 Q6NYC1 1/20 0.49
NUDT1 P36639 1/20 0.49
LMNA P02545 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 2/20 0.47
PKM P14618 1/20 0.47
NPC1 O15118 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
NAMPT P43490 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2052901 0.77 JMJD6 (0.52) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL25343055 0.77 KMT2A (0.64) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL20767134 0.76 JMJD6 (0.44) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL8221283 0.74 PKM (0.51) ALDH1A1KMT2AKDM4ETSHRJMJD6
SCHEMBL15279104 0.73 ALDH1A1 (0.57) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL31474370 0.73 JMJD6 (0.52) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL8121938 0.72 ALDH1A1 (0.60) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL2742976 0.72 HCAR2 (0.54) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL10406368 0.72 KMT2A (0.49) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL4258913 0.72 PKM (0.43) ALDH1A1KMT2AMEN1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0116494-B1 PYRIDAZINE DERIVATIVES WITH A PSYCHOTROPE ACTIVITY, PROCESS FOR THEIR PREPARATION, INTERMEDIATES AND MEDICINES CONTAINING THEM SANOFI S.A. (FR) 1988-01-27 EP claimed
EP-4323066-A1 MEK INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2024-02-21 EP disclosed
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-30 US disclosed
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-30 US disclosed
US-11685719-B2 Pyridinone MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2023-06-27 US disclosed
US-11685719-B2 Pyridinone MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2023-06-27 US disclosed
US-20230053465-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-02-23 US disclosed
WO-2023283338-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-01-12 WO disclosed
WO-2022221866-A1 MEK INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-10-20 WO disclosed
US-7928106-B2 2-[2-(2,5-Difluoro-phenyl)-ethoxymethyl]-3H-pteridin-4-one; 2-2-(3-Fluoro-phenyl)-ethoxymethyl]-3H-pyrimido[4,5-d]pyrimidin-4-one; (5-Oxo-5,6-dihydro-pyrimido[4,5-c]pyridazin-7-ylmethyl)-carbamic acid benzyl ester, useful in treating diseases which are modulated by HM74A agonists e.g. dyslipidemia HOFFMANN-LA ROCHE INC. (US) 2011-04-19 US disclosed
EP-2139895-A1 AZA-PYRIDOPYRIMIDINONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-01-06 EP disclosed
WO-2008116742-A1 AZA-PYRIDOPYRIMIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-02 WO disclosed
US-20080234277-A1 NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230053465-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF ENPP2, PLP2, PDXK ALDH1A1 2928/4885KMT2A 791/4885MEN1 1179/4885
US-20230382864-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF ENPP2, PLP2, PDXK ALDH1A1 2928/4885KMT2A 791/4885MEN1 1179/4885
US-20080234277-A1 NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES CHRM1, CHRM2, CHRM4 ALDH1A1 543/4885KMT2A 893/4885MEN1 1109/4885
US-11685719-B2 Pyridinone MK2 inhibitors and uses thereof ENPP2, PLP2, PDXK ALDH1A1 2928/4885KMT2A 791/4885MEN1 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.